Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas — (March 26, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2025 […]
Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes AUSTIN, Texas — (March 25, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming 2025 […]
AUSTIN, Texas — (March 4, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 17-19, 2025 in Milan, Italy. In […]
Researching Novel Diabetes Gene Therapy Using Potentially Re-Dosable Non-Viral Delivery System Strategic Collaboration with CDMO Partner Positions Genprex as a Thought-Leader in Diabetes Market AUSTIN, Texas — (Feb. 19, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the […]
Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development AUSTIN, Texas — (Feb. 18, 2025) —Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with […]
New publication indicates that NPRL2 gene therapy has marked single-agent activity in anti-PD1 resistant non-small cell lung cancer xenografts AUSTIN, Texas — (Feb. 13, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at a […]
Expects to Complete Enrollment of First 25 Patients in Phase 2 Expansion Study During Second Half of 2025 for Interim Analysis Acclaim-3 Study Has FDA Orphan Drug and Fast Track Designations AUSTIN, Texas — (Jan. 23 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients […]
AUSTIN, Texas — (Jan. 6, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating in investor, industry and business development meetings at the 43rd Annual J.P. Morgan Healthcare […]
Genprex Completes Phase 1 Dose Escalation Portion of Acclaim-3 Clinical Trial Results from Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of REQORSA and Tecentriq in ES-SCLC Patients AUSTIN, Texas — (Dec. 16, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and […]
Ryan Confer, President and Chief Executive Officer at Genprex, sat down with the Marathon Money podcast to discuss the Company’s pipeline of gene therapies for cancer and diabetes. Watch the interview here: https://www.youtube.com/watch?v=blIpam7eBTc